SCHEMBL1123948

SCHEMBL1123948

CNc1nc(C=Cc2ccc(OC)cc2)nc(N2CCOCC2)c1N

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 4/20 0.47
MAPT P10636 5/20 0.43
KDM4E B2RXH2 1/20 0.43
NOS1 P29475 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HTT P42858 1/20 0.41
POLB P06746 1/20 0.41
ATM Q13315 1/20 0.41
MERTK Q12866 1/20 0.41
ENPP1 P22413 1/20 0.40
PKM P14618 1/20 0.40
MCHR1 Q99705 1/20 0.39
PIK3CA P42336 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1123946 1.00 FLT3 (0.47) FLT3MAPTKDM4ENOS1MEN1
SCHEMBL1123930 0.91 FLT3 (0.47) FLT3MAPTKDM4ENOS1MEN1
SCHEMBL1123926 0.91 FLT3 (0.47) FLT3MAPTKDM4ENOS1MEN1
SCHEMBL1123917 0.88 FLT3 (0.45) FLT3MAPTKDM4ENOS1MEN1
SCHEMBL1123916 0.88 FLT3 (0.45) FLT3MAPTKDM4ENOS1MEN1
SCHEMBL1123906 0.87 FLT3 (0.52) FLT3MAPTKDM4ENOS1NPC1
SCHEMBL1123908 0.87 FLT3 (0.52) FLT3MAPTKDM4ENOS1NPC1
SCHEMBL1123794 0.86 HRH4 (0.46) FLT3MAPTKDM4ENOS1L3MBTL1
SCHEMBL1123790 0.86 HRH4 (0.46) FLT3MAPTKDM4ENOS1L3MBTL1
SCHEMBL1123732 0.85 FLT3 (0.60) FLT3MAPTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563715-B2 Pyrimidine derivative having cell protecting effect and uses thereof ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2013-10-22 US claimed
US-20110152519-A1 PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2011-06-23 US claimed
EP-2284160-A1 PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2011-02-16 EP claimed
US-8563715-B2 Pyrimidine derivative having cell protecting effect and uses thereof ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2013-10-22 US disclosed
EP-2284160-B1 PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF ZENYAKU KOGYO KK (JP) 2013-05-15 EP disclosed
US-20110152519-A1 PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2011-06-23 US disclosed
EP-2284160-A1 PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2011-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152519-A1 PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF CASP3, DPYD, CASP1 FLT3 3375/4885MAPT 350/4885KDM4E 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.